Patents by Inventor Jeffrey TESTANI,

Jeffrey TESTANI, has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240115785
    Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.
    Type: Application
    Filed: December 15, 2023
    Publication date: April 11, 2024
    Applicant: Sequana Medical NV
    Inventors: Jeffrey TESTANI, Christopher McINTYRE, Ian CROSBIE, Oliver GOEDJE
  • Patent number: 11950925
    Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: April 9, 2024
    Assignee: REPRIEVE CARDIOVASCULAR, INC.
    Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
  • Patent number: 11844890
    Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: December 19, 2023
    Assignee: Sequana Medical NV
    Inventors: Jeffrey Testani, Christopher McIntyre, Ian Crosbie, Oliver Goedje
  • Publication number: 20230240600
    Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.
    Type: Application
    Filed: April 5, 2023
    Publication date: August 3, 2023
    Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
  • Publication number: 20230158221
    Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.
    Type: Application
    Filed: January 20, 2023
    Publication date: May 25, 2023
    Applicant: Sequana Medical NV
    Inventors: Jeffrey TESTANI, Christopher McINTYRE, Ian CROSBIE, Oliver GOEDJE
  • Patent number: 11627912
    Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: April 18, 2023
    Assignee: Reprieve Cardiovascular, Inc.
    Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
  • Patent number: 11559618
    Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: January 24, 2023
    Assignee: Sequana Medical NV
    Inventors: Jeffrey Testani, Christopher McIntyre, Ian Crosbie, Oliver Goedje
  • Publication number: 20230010793
    Abstract: The present technology includes devices, systems, and method for managing a patient's urine output. In some embodiments, an exemplary method includes receiving an estimated amount of excess fluid for the patient; obtaining a urine output rate of the patient; obtaining a diuretic dosage rate of the patient; obtaining (i) a first input corresponding to a percentage of an actual amount of net fluid loss relative to the estimated amount of excess fluid, and/or (ii) a second input corresponding to an estimated amount of fluid remaining; and based on the first input and/or the second input, providing an output associated with adjusting the fluid therapy. Providing the output can include providing an indication with instructions for increasing the patient's urine output by administering an additional diuretic and/or increasing infusion of hydration fluid to the patient.
    Type: Application
    Filed: July 12, 2022
    Publication date: January 12, 2023
    Inventors: Jeffrey Testani, Andrew Halpert, Kenneth John Luppi, Antony Jonathan Fields, Mark Richard Pacyna, Arslan Mazhar Malik
  • Publication number: 20230001065
    Abstract: Enhanced systems and methods for performing Direct Sodium Removal (DSR) therapy are provided in which an implantable device includes a variable speed motor-driven pump that may be programmed to output different flow rates at different stages of a DSR therapy session, wherein the system monitors operational parameters of the pump and is configured to generate an alarm condition indicative of a fault that may be displayed on a patient's smartphone to permit corrective action, and in which a catheter set implanted with the implantable device enables a DSR solution may be instilled into the patient's peritoneal cavity using a peritoneal catheter that is subsequently used to remove the DSR solution and sodium-rich ultrafiltrate from the peritoneal cavity to the patient's bladder.
    Type: Application
    Filed: September 6, 2022
    Publication date: January 5, 2023
    Applicant: Sequana Medical NV
    Inventors: Andreas WIRTH, Jeffrey TESTANI, Ian CROSBIE, Oliver GOEDJE
  • Publication number: 20220313158
    Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.
    Type: Application
    Filed: June 13, 2022
    Publication date: October 6, 2022
    Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
  • Publication number: 20220257843
    Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.
    Type: Application
    Filed: May 2, 2022
    Publication date: August 18, 2022
    Applicant: Sequana Medical NV
    Inventors: Jeffrey TESTANI, Christopher McINTYRE, Ian CROSBIE, Oliver GOEDJE
  • Publication number: 20220195033
    Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
    Type: Application
    Filed: November 4, 2021
    Publication date: June 23, 2022
    Inventors: Jeffrey TESTANI, Veena RAO, Rahul KAKKAR, Madhav N. DEVALARAJA, Chih-Hung LO
  • Patent number: 11357446
    Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: June 14, 2022
    Assignee: Reprieve Cardiovascular, Inc.
    Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
  • Patent number: 11203636
    Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: December 21, 2021
    Assignees: YALE UNIVERSITY, Novo Nordisk A/S
    Inventors: Jeffrey Testani, Veena Rao, Rahul Kakkar, Madhav N. Devalaraja, Chih-Hung Lo
  • Publication number: 20210169408
    Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 10, 2021
    Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
  • Publication number: 20200340031
    Abstract: The present invention relates to compositions and methods for binding and detecting or measuring renalase. In one embodiment, the renalase binding molecule measures renalase amount or activity. Thus, in diseases and conditions where a measurement of renalase is beneficial, such renalase binding molecules may act as diagnostics.
    Type: Application
    Filed: December 27, 2018
    Publication date: October 29, 2020
    Inventors: Gary Desir, Jeffrey Testani, Veena Rao
  • Publication number: 20200079846
    Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
    Type: Application
    Filed: February 1, 2018
    Publication date: March 12, 2020
    Inventors: Jeffrey TESTANI,, Veena RAO, Rahul KAKKAR, Madhav N. DEVALARAJA, Chih-Hung LO